Radical Prostatectomy as Primary Treatment of High-risk Prostate Cancer

Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer

(2011) Stephen A. Boorjian et al.   CANCER

Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study

(2011) Tanya B. Dorff et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Clinical Trial of Neoadjuvant Ketoconazole and Docetaxel Chemotherapy Before Radical Prostatectomy in High Risk Patients

(2011) Paul R. Womble et al.   JOURNAL OF UROLOGY

Radical Prostatectomy for High-risk Prostate Cancer Defined by Preoperative Criteria: Oncologic Follow-up in National Multicenter Study in 813 Patients and Assessment of Easy-to-use Prognostic Substratification

(2011) Guillaume Ploussard et al.   UROLOGY

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients

(2010) Guillaume Ploussard et al.   BJU INTERNATIONAL

Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer

(2010) Matthew R. Cooperberg et al.   CANCER

Outcome Predictors of Radical Prostatectomy in Patients With Prostate-Specific Antigen Greater Than 20 ng/ml: A European Multi-Institutional Study of 712 Patients

(2010) Martin Spahn et al.   EUROPEAN UROLOGY

A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988–2006

(2010) Firas Abdollah et al.   EUROPEAN UROLOGY

Metastasis After Radical Prostatectomy or External Beam Radiotherapy for Patients With Clinically Localized Prostate Cancer: A Comparison of Clinical Cohorts Adjusted for Case Mix

(2010) Michael J. Zelefsky et al.   JOURNAL OF CLINICAL ONCOLOGY

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study

(2010) Michel Bolla et al.   LANCET ONCOLOGY

Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer

(2009) Guillaume Ploussard et al.   BJU INTERNATIONAL

Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer

(2009) Jacqueline Vuky et al.   CANCER

Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95

(2009) Thomas Wiegel et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

(2009) D.R. Shepard et al.   JOURNAL OF UROLOGY

Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial

(2009) Ian M. Thompson et al.   JOURNAL OF UROLOGY

Duration of Androgen Suppression in the Treatment of Prostate Cancer

(2009) Michel Bolla et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life

(2009) G Ploussard et al.   PROSTATE CANCER AND PROSTATIC DISEASES

What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer?

(2009) Stacy Loeb et al.   UROLOGY

A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma

(2008) M.D. Shelley et al.   CANCER TREATMENT REVIEWS

Long-Term Rates of Undetectable PSA with Initial Observation and Delayed Salvage Radiotherapy after Radical Prostatectomy

(2008) Stacy Loeb et al.   EUROPEAN UROLOGY

Long-Term Outcome Following Three-Dimensional Conformal/Intensity-Modulated External-Beam Radiotherapy for Clinical Stage T3 Prostate Cancer

(2008) Michael J. Zelefsky et al.   EUROPEAN UROLOGY

Prostate Cancer–Specific Survival Following Salvage Radiotherapy vs Observation in Men With Biochemical Recurrence After Radical Prostatectomy

(2008) Bruce J. Trock   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer

(2008) Eric M. Horwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Phase II Study of Combined Neoadjuvant Docetaxel and Hormone Therapy Before Radical Prostatectomy for Patients With High Risk Localized Prostate Cancer

(2008) Kim N. Chi et al.   JOURNAL OF UROLOGY

The Specific Definition of High Risk Prostate Cancer Has Minimal Impact on Biochemical Relapse-Free Survival

(2008) Carvell T. Nguyen et al.   JOURNAL OF UROLOGY

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

(2008) Anders Widmark et al.   LANCET

Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: A systematic review and meta-analysis

(2008) Scott C. Morgan et al.   RADIOTHERAPY AND ONCOLOGY

Pilot Trial of Adjuvant Paclitaxel Plus Estramustine in Resected High-Risk Prostate Cancer

(2008) Jeremy P. Cetnar et al.   UROLOGY

Veterans Affairs Cooperative Studies Program Study 553: Chemotherapy After Prostatectomy, a Phase III Randomized Study of Prostatectomy Versus Prostatectomy with Adjuvant Docetaxel for Patients with High-Risk, Localized Prostate Cancer

(2008) Bruce Montgomery et al.   UROLOGY

EAU Guidelines on Prostate Cancer

(2007) Axel Heidenreich et al.   EUROPEAN UROLOGY